An update on drugs for the treatment of menopausal symptoms

Bibliography

• Archer DF, Sturdee DW, Baber R, et al. Menopausal hot flushes and night sweats: where are we now? Climacteric 2011;14(5):515-28
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11(1):11-33
   PubMed Web of Science ®Google Scholar
• Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008;23(9):1507-13
   PubMed Web of Science ®Google Scholar
• Smith P. Estrogens and the urogenital tract studies on steroid hormone receptors and a clinical study on a new estradiol releasing vaginal ring. Acta Obstet Gynecol Scand Suppl 1993;157:1-26
   PubMedGoogle Scholar
• Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014;17(1):3-9
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause 2014;21(10):1063-8
   PubMed Web of Science ®Google Scholar
• Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20(9):888-902
   PubMed Web of Science ®Google Scholar
• Palacios S, Henderson VW, Siseles N, et al. Age of menopause and impact of climacteric symptoms by geographical region. Climacteric 2010;13:419-28
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Schneider HP, Panay N, Nijland EA. The EuropeanMenopause Survey 2005: women’s perceptions on the menopause and postmenopausal hormone therapy. Gynecol Endocrinol 2006;22:369-75
   PubMed Web of Science ®Google Scholar
• Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001;153:865-74
   PubMed Web of Science ®Google Scholar
• Chedraui P, Blumel JE, Baron G, et al. Impaired quality of life among middle aged women: a multicentre Latin American study. Maturitas 2008;61:323-9
   PubMed Web of Science ®Google Scholar
• Lam PM, Leung TN, Haines C, Chung TK. Climacteric symptoms and knowledge about hormone replacement therapy among Hong Kong Chinese women aged 40–60 years. Maturitas 2003;45:99-107
   PubMed Web of Science ®Google Scholar
• Grodstein F1, Stampfer M. :The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38(3):199-210
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291(14):1701-12
   PubMed Web of Science ®Google Scholar
• Simon JA. What’s new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric 2012;15(Suppl 1):3-10
   PubMed Web of Science ®Google Scholar
• De Villiers TJ, Gass ML, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013;16(2):203-4
   PubMed Web of Science ®Google Scholar
• Palacios S, Mejía Ríos A. Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women. Drugs Today (Barc) 2015;51(2):107-16
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-38
   PubMed Web of Science ®Google Scholar
• Yu H, Racketa J, Chines AA, Mirkin S. Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women. Climacteric 2013;16:252-7
   PubMed Web of Science ®Google Scholar
• Palacios S. Tibolone: what does tissue specific activity mean? Maturitas 2001;37(3):159-65
   PubMed Web of Science ®Google Scholar
• Palacios S, Menendez C, Jurado AR, et al. Changes in sex behaviour after menopause: effects of tibolone. Maturitas 1995;22(2):155-61
   PubMed Web of Science ®Google Scholar
• Liu JH. Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms. Am J Med 2005;118(Suppl 12B):88-92
   PubMedGoogle Scholar
• Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004;104(4):824-36
   PubMed Web of Science ®Google Scholar
• Setchell KD, Brown NM, Zimmer-Nechemias L, et al. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr 2002;76(2):447-53
   PubMed Web of Science ®Google Scholar
• Freedman RR. Hot flashes: behavioral treatments, mechanisms, and relation to sleep. Am J Med 2005;118(Suppl 12B):124-30
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Barton DL, Quin R. Nonestrogenic management of hot flashes. J Clin Oncol 2011;29(29):348-6
   Web of Science ®Google Scholar
• Lilue M, Palacios S. [Non-hormonal treatment for vasomotor symptoms during menopause: role of desvenlafaxine]. Ginecol Obstet Mex 2009;77(10):475-81
   PubMedGoogle Scholar
• Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013;20(10):1027-35
   PubMed Web of Science ®Google Scholar
• FDA approves the first non-hormonal treatment for hot flashes. Available from: www.fda.gov/NewsEvents/.../ucm359030.htm [Last accessed 28 June 2013]
   Google Scholar
• Vercellini P, Sacerdote P, Trespidi L, et al. Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study. Fertil Steril 1994;62(5):938-42
   PubMed Web of Science ®Google Scholar
• De Leo V, Morgante G, Musacchio MC, et al. The safety of veralipride. Expert Opin Drug Saf 2006;5(5):695-701
   PubMed Web of Science ®Google Scholar
• Lindsay R, Hart DM. Failure of response of menopausal vasomotor symptoms to clonidine.Maturitas. 1978;1(1):21-5
   Google Scholar
• Nesheim BI, Saetre T. Reduction of menopausal hot flushes by methyldopa. A double blind crossover trial. Eur J Clin Pharmacol 1981;20(6):413-16
   PubMed Web of Science ®Google Scholar
• Yadav M, Volkar J. Potential role of gabapentin and extended-release gabapentin in the management of menopausal hot flashes. Int J Gen Med 2013;6:657-64
   PubMedGoogle Scholar
• Hellström AC, Muntzing J. The pollen extract Femal--a nonestrogenic alternative to hormone therapy in women with menopausal symptoms. Menopause 2012;19(7):825-9
   PubMed Web of Science ®Google Scholar
• Beer AM, Osmers R, Schnitker J, et al. Efficacy of black cohosh (Cimicifuga racemosa) medicines for treatment of menopausal symptoms - comments on major statements of the Cochrane Collaboration report 2012 "black cohosh (Cimicifuga spp.) for menopausal symptoms (review)". Gynecol Endocrinol 2013;29(12):1022-5
   PubMed Web of Science ®Google Scholar
• Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009;63:138-41
   PubMed Web of Science ®Google Scholar
• Rahn DD, Carberry C, Sanses TV, et al. Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014;124(6):1147-56
   PubMed Web of Science ®Google Scholar
• Palacios S. Managing urogenital atrophy. Maturitas 2009;63:315-18
   PubMed Web of Science ®Google Scholar
• Constantine GD, Bruyniks N, Princic N, et al. Incidence of Genitourinary Conditions in Women with a Diagnosis of Vulvar/Vaginal Atrophy. Curr Med Res Opin 2014;30(1):143-8
   PubMed Web of Science ®Google Scholar
• Nachtigall E. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-80
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Cancelo MJ, Villero J, et al. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52(Suppl 1):S46-52
   PubMed Web of Science ®Google Scholar
• Brown JM, Hess KL, Brown S, et al. Intravaginal practices and risk of bacterial vaginosis and candidiasis infection among a cohort of women in the United States. Obstet Gynecol 2013;121(4):773-80
   PubMed Web of Science ®Google Scholar
• Capon A, Mordon S. Can thermal lasers promote skin wound healing? Am J Clin Dermatol 2003;4:1-12
   PubMed Web of Science ®Google Scholar
• Sherling M, Friedman PM, Adrian R, et al. Consensus recommendations on the use of an erbium-doped 1,550-nm fractionated laser and its applications in dermatologic laser surgery. Dermatol Surg 2010;36(4):461-9
   PubMed Web of Science ®Google Scholar
• Gaspar A, Addamo G, Brandi H. Vaginal fractional CO2 laser: a minimally invasive option for vaginal rejuvenation. Am J Cosmet Surg 2011;28:156-62
   Google Scholar
• Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 2014;17:363-9
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Levancini M. Short-term effect of vaginal erbium laser on the genitourinary syndrome of menopause. Minerva Ginecol 2015;67(2):97-102
   PubMed Web of Science ®Google Scholar
• Sánchez-Borrego R, Manubens M, Navarro MC, et al. Spanish Menopause Society. Position of the Spanish Menopause Society regarding vaginal health care in postmenopausal women. Maturitas 2014;78(2):146-50
   PubMed Web of Science ®Google Scholar
• Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev 2012;9
   Google Scholar
• Yildirim B, Kaleli B, Düzcan E, Topuz O. The effects of postmenopausal Vitamin D treatment on vaginal atrophy. Maturitas 2004;49(4):334-7
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society. The 2012 Hormone therapy position statement of the north american menopause society. Menopause 2012;19:257-71
   PubMed Web of Science ®Google Scholar
• Cardozo L, Bachmann G, McClish D, et al. Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-7
   PubMed Web of Science ®Google Scholar
• Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and Q6 treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstet Gynecol 2005;105:1063-73
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, et al. A randomized, placebo-and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281-9
   PubMed Web of Science ®Google Scholar
• McLendon AN, Clinard VB, Woodis CB. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women. Pharmacotherapy 2014;34(10):1050-60
   PubMed Web of Science ®Google Scholar
• Press Announcements > FDA approves Osphena for. www.fda.gov/NewsEvents/.../ucm341128.htm
   Google Scholar
• European Medicines Agency - Find medicine - Senshio. www.ema.europa.eu/ema/index.jsp
   Google Scholar
• Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480-6
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20(6):623-30
   PubMed Web of Science ®Google Scholar
• Simon JA, Lin VH, Radovich C, Bachmann GA. The Ospemifene Study Group. One year long-term safety extension study of ospemifeno for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013;20(4):418-27
   PubMed Web of Science ®Google Scholar
• Manonai J, Songchitsomboon S, Chanda K, et al. The effect of a soy-rich diet on urogenital atrophy: a randomized crossover trial. Maturitas 2006;54:135-40
   PubMed Web of Science ®Google Scholar
• Hidalgo LA, Chedraui PA, Morocho N, et al. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, doubleblind, placebo-controlled study. Gynecol Endocrinol 2005;21:257-64
   PubMed Web of Science ®Google Scholar
• Bedell S, Nachtigall M, Naftolin F. The pros and cons of plant estrogens for menopause. J Steroid Biochem Mol Biol 2014;139:225-36
   PubMed Web of Science ®Google Scholar
• Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006;CD001500
   PubMed Web of Science ®Google Scholar
• Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climateric 2010;13(13):219-27
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509-22
   PubMed Web of Science ®Google Scholar
• Lynch C. Vaginal estrogen therapy for the treatment of atrophic vaginitis. J Womens Health (Larchmt) 2009;18:1595-606
   PubMed Web of Science ®Google Scholar
• Al-Baghdadi O, Ewies AAA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009;12:91-105
   PubMed Web of Science ®Google Scholar
• Baldassarre M, Perrone AM, Giannone FA, et al. Androgen receptor expression in the human vagina under different physiological and treatment conditions. Int J Impot Res 2013;25:7-11
   PubMed Web of Science ®Google Scholar
• Berman JR, Almeida FG, Jolin J, et al. Correlation of androgen receptors, aromatase and 5-alpha reductase in the human vagina with menopausal status. Fertil Steril 2003;79:925-31
   PubMed Web of Science ®Google Scholar
• Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011;16:424-31
   PubMed Web of Science ®Google Scholar
• De Scheffers CS, Armstrong S, Cantineau AE, et al. dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane. Database Syst Rev 2015;1:CD011066
   PubMedGoogle Scholar
• Labrie F, Cusan L, Gomez JL, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;111:178-94
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Effect of Intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual function in postmenopausal women. Menopause 2009;16(5):923-31
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al.Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282-8
   PubMed Web of Science ®Google Scholar